Shanghai Junshi Biosciences Co Ltd Class H 01877
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- HK$19.30
- Day Range
- HK$17.40–19.30
- 52-Week Range
- HK$15.25–32.62
- Bid/Ask
- HK$18.07 / HK$18.10
- Shares Outstanding
- 1.03B
- Market Cap
- HK$18.54B
- Volume/Avg
- 562,600 / 3M
Key Statistics
- Price/Earnings (Normalized)
- 512.18
- Price/Sales
- 5.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,903
- Website
- https://www.junshipharma.com
Valuation
|
Metric
|
01877
|
|---|---|
Price/Earnings (Normalized) | 512.18 |
Price/Book Value | 2.98 |
Price/Sales | 5.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
01877
|
|---|---|
Quick Ratio | 1.55 |
Current Ratio | 1.78 |
Interest Coverage | −5.05 |
Quick Ratio
01877
Profitability
|
Metric
|
01877
|
|---|---|
Return on Assets (Normalized) | 0.27% |
Return on Equity (Normalized) | 0.57% |
Return on Invested Capital (Normalized) | 0.73% |
Return on Assets
01877
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|w&!@^b | LOCK|&!mQw | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|B%!#&rr | LOCK|@@^$N | $76B | |||
| Moderna Inc
MRNA
| LOCK|@r#Z><z | LOCK|c?M | $75B | |||
| argenx SE ADR
ARGX
| LOCK|@B@br$@ | LOCK|Zl& | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?hGWc% | LOCK|!#^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Lc$S@zJ | LOCK|rkHqY | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|f@f>M&t$ | LOCK|lBH<% | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|?nT%>& | LOCK|@< | $24B | |||
| Incyte Corp
INCY
| LOCK|K&^X#K | LOCK|<$s | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|LjFYcC | LOCK|k%< | $15B |
United States